Tuberculosis remains the number one cause of infectious mortality worldwide A candidate mRNA vaccine that boosts immunity ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic insider stock purchases ...

This was in addition to the $176 million awarded by the US Department of Health and Human Services (HHS) last year to complete the late-stage development and testing of a pre-pandemic mRNA-based ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials ... The study found that the new mRNA vaccine was successful in ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials ... The study found that the new mRNA vaccine was successful in ...

The vaccine is at the pre-clinical trial stage ... The vaccine is based on mRNA technology, where genetic instructions are used to trigger an immune response in the body, as opposed to using ...